Cigna Group (CI) Stock Analysis and Metrics

Sector: Healthcare Industry: Healthcare Plans CIK: 0001739940

ROIC (Qtr) 0.09

Total Debt (Qtr) 31.46 Bn

Revenue Growth (1y) (Qtr) -19.70

Add ratio to table...

About

Cigna Group, also known as CI, is a prominent player in the healthcare industry, dedicated to improving the health and well-being of individuals, families, and businesses. The company's operations span across various segments, including Evernorth Health Services and Cigna Healthcare, each offering a diverse range of health solutions and capabilities. Evernorth Health Services, a broad spectrum of independent and coordinated health solutions, is designed to enhance the healthcare system and promote healthier lives. This segment includes pharmacy...

Cigna Group, also known as CI, is a prominent player in the healthcare industry, dedicated to improving the health and well-being of individuals, families, and businesses. The company's operations span across various segments, including Evernorth Health Services and Cigna Healthcare, each offering a diverse range of health solutions and capabilities.

Evernorth Health Services, a broad spectrum of independent and coordinated health solutions, is designed to enhance the healthcare system and promote healthier lives. This segment includes pharmacy benefits, home delivery pharmacy, specialty pharmacy, specialty distribution, and care delivery and management solutions. Pharmacy benefits offered by Evernorth Health Services provide high-quality, cost-effective pharmacy care through various services such as drug claims adjudication, retail pharmacy network administration, drug utilization review, and drug formulary management. Home delivery pharmacy services offer free standard shipping of medications directly to customers' homes, usually in a 90-day supply. Specialty pharmacy services, including Accredo, focus on dispensing drugs that require a higher level of clinical service and support.

Cigna Healthcare, on the other hand, offers comprehensive medical and coordinated solutions to clients and customers. The segment includes U.S. Healthcare and International Health operating segments, providing medical plans and specialty benefits and solutions for insured and self-insured clients, Medicare Advantage, Medicare Supplement, and Medicare Part D plans for seniors, and individual health insurance plans.

Cigna's competitive advantages lie in its deep clinical expertise, robust data and insights, focus on developing innovative solutions, and consultative approach driven by an experienced and talented team. These strengths enable the company to solve challenges in various areas, including pharmacy benefits, home delivery pharmacy, specialty pharmacy, specialty distribution, and care delivery and management solutions. Cigna's customers include health plans, employers, governmental organizations, and healthcare providers, with significant clients being major health plans, self-insured employers, and government agencies. The company's pharmacy benefits management services cater to over 100 million customers, and its specialty pharmacy services serve over 1 million customers.

In terms of growth strategy, Cigna Healthcare aims to engage customers in their health, partner with providers to improve their performance, and connect customers and providers through aligned health goals, incentives, and actionable information. This approach enables informed decisions and drives better outcomes. Fueled by advanced insights and predictive analytics, Cigna Healthcare continues to develop targeted, innovative solutions that span the healthcare delivery system and can be applied to various providers.

Cigna's position within the industry is solid, with a focus on enhancing the health and vitality of those it serves. The company's partnerships with health plans, employers, governmental organizations, and healthcare providers enable it to provide high-quality, cost-effective healthcare services to its customers. Cigna's competitive advantages, growth strategy, and position within the industry make it a strong contender in the healthcare industry.

In addition to its core offerings, Cigna Group invests in digital, data, and technology to cultivate robust digital-first capabilities, delivering value for clients, customers, and stakeholders. The company's human capital management strategy is designed to attract, retain, and develop a diverse and talented workforce, while its environmental, social, and governance (ESG) framework aims to transform the health ecosystem into one that is well-functioning, sustainable, accessible, and equitable.

Cigna Group operates under the regulations of federal, state, and international legislative bodies and agencies, subject to regular examinations, audits, and potential enforcement actions. Despite these regulatory challenges, Cigna remains committed to its mission of improving the health and vitality of those it serves, making it a notable player in the healthcare industry.

Investment thesis

Bull case

The 11% year‑over‑year revenue expansion in 2025, driven by specialty pharmacy growth and stronger employer‑sponsored health plans, demonstrates a resilient demand base that can sustain upside. A 14% increase in specialty revenue and a 13% rise in specialty prescriptions illustrate a high‑margin business that continues to capture rising drug spend, particularly in the biosimilar and specialty generic space. The company’s plan to roll out a rebate‑free pharmacy benefit model by 2027, with an expected 50% adoption of the new model by EverNorth and 80% adoption of the Cigna Healthcare guarantee plan, preserves margin integrity while opening a larger customer footprint. The firm’s disciplined pricing strategy, evidenced by the 88% medical loss ratio in the quarter, shows effective cost management even in a high‑cost environment, reinforcing confidence in its pricing power. The integration of AI‑driven digital tools—such as real‑time cost trackers and provider‑matching tools—offers scalable enhancements to member engagement, potentially translating into higher customer retention and premium growth. Strategic investments, notably the Shield Health Solutions acquisition, position the company to capture hospital and health‑system pharmacy opportunities, extending its specialty footprint into high‑volume clinical sites. The partnership ecosystem, including collaborations with Headspace for mental health, Progyny for fertility, and Caret for employer benefits, creates cross‑sell opportunities that could increase the share of wallet in existing accounts. Finally, the FTC settlement and the resulting 7 billion dollar out‑of‑pocket relief over ten years provide a tangible, long‑term cost‑reduction catalyst that can improve member satisfaction and drive plan renewals, creating a virtuous cycle of growth and profitability.
Cigna’s emphasis on customer‑centric innovation, such as the Clarity platform that offers a single digital front door for pharmacy, dental, and supplemental services, signals a shift toward integrated, value‑based care models that align with payer and provider incentives for improved outcomes. By leveraging data analytics to personalize care pathways and streamline authorization processes, the company reduces administrative burden, potentially lowering the medical loss ratio over time and improving its risk‑sharing profile. The firm’s commitment to expanding generics and biosimilars—highlighted by its zero out‑of‑pocket initiatives for Humira and Stellara—places it at the forefront of the upcoming 100 billion dollar specialty drug savings window, a sector projected to grow at double‑digit rates. The ability to capture market share in specialty pharmacy, a business that now accounts for roughly 35% of the company’s revenue, suggests a structural shift that could insulate the firm from the volatility seen in traditional insurance segments. The strategic focus on employer‑sponsored plans, particularly in the middle and select markets, aligns with a demographic that is less sensitive to macroeconomic swings and more oriented toward comprehensive benefits packages. Moreover, the company’s shift away from Medicare Advantage and the Obamacare business eliminates the regulatory headwinds and margin compression associated with those lines, freeing capital to invest in higher‑growth platforms. The firm’s capital allocation strategy—returning over 5 billion dollars to shareholders and maintaining a debt‑to‑capitalization ratio below 43%—provides a buffer for future acquisitions or investment in technology infrastructure that could accelerate the rollout of its new PBM model. Collectively, these initiatives represent catalysts that the market may have undervalued, positioning the company for sustainable long‑term earnings expansion.
The company’s forward guidance for 2026, projecting adjusted EPS of at least 30.25 and revenue of approximately 280 billion, remains in line with its multiyear growth trajectory, underscoring management’s confidence in execution. The forecasted medical cost ratio of 83.7% to 84.7% suggests a moderate increase, but the firm’s margin improvement plan and pricing actions in the stop‑loss and individual exchange businesses indicate that it is actively working to offset this trend. By projecting a first‑quarter medical loss ratio below 81%, the company signals a seasonality advantage that could provide a cushion against year‑over‑year cost pressure. The 2026 cash flow guidance of roughly 9 billion in operating cash, while lower than 2025, remains healthy relative to the capital deployment of 1.3 billion in cap‑ex and 1.6 billion in dividends, preserving upside potential for future growth. Importantly, the firm’s commitment to a 40% debt‑to‑capitalization target by 2028 reflects a disciplined approach to leverage that can support continued expansion of its pharmacy benefit services platform. The planned investment in the new rebate‑free model, projected to start generating earnings in the latter half of 2026, aligns with the company’s strategic focus on long‑term value creation. The company's robust share repurchase program, which reduced the share count and boosted earnings per share, will enhance shareholder value if the company continues to execute on its growth plan. Together, these financial drivers support a bullish thesis that the market may have underestimated the firm’s ability to sustain and grow earnings in a complex regulatory environment.
The company’s digital transformation, highlighted by AI‑powered tools and a seamless integration platform for member engagement, offers a clear path to differentiation in a highly competitive health‑services marketplace. By providing real‑time cost visibility and provider matching, the firm reduces uncertainty for members, thereby increasing plan loyalty and reducing churn. The integration of these tools across its three business platforms—specialty pharmacy, pharmacy benefit services, and employer health benefits—creates operational synergies that can lower per‑member acquisition costs. The expansion of the digital front door through the Clarity platform simplifies the customer experience, potentially driving higher utilization of its own services and improving data capture for future predictive analytics. The company's focus on mental health partnerships, such as its collaboration with Headspace, addresses a growing societal need while creating cross‑sell opportunities within its existing employer‑sponsored plans. These digital and partnership initiatives collectively enhance the company's competitive moat, allowing it to capture incremental revenue in a crowded market. The ability to scale these technologies across its vast member base further amplifies their impact on profitability, positioning the firm for continued upside.
The strategic shift toward a pharmacy benefit management model that eliminates rebates aligns the company with regulatory trends favoring transparency and cost containment, potentially positioning it as an industry leader in the evolving PBM landscape. The company’s proactive engagement with the FTC and the passage of federal PBM reform legislation demonstrate its ability to navigate regulatory uncertainty and shape policy outcomes. The new rebate‑free model promises a more predictable margin profile while reducing the risk associated with negotiated rebates, a vulnerability in the traditional PBM business. By shifting the revenue mix toward fee‑based earnings, the company mitigates the volatility that has historically plagued PBMs due to changes in manufacturer pricing or insurer negotiations. The model’s emphasis on patient‑centric cost savings could attract employers seeking to control pharmacy spend, driving further market penetration. The company’s ability to secure high‑profile clients, such as its guarantee plan adoption by major employers, signals market acceptance of this new model. This regulatory and market alignment positions the company to capture a larger share of the growing pharmacy benefit services segment, a trend that other PBMs may struggle to replicate due to legacy contracts and rebate structures. Consequently, the market may have undervalued the firm’s advantage in this structural shift, presenting a bullish opportunity.

The 11% year‑over‑year revenue expansion in 2025, driven by specialty pharmacy growth and stronger employer‑sponsored health plans, demonstrates a resilient demand base that can sustain upside. A 14% increase in specialty revenue and a 13% rise in specialty prescriptions illustrate a high‑margin business that continues to capture rising drug spend, particularly in the biosimilar and specialty generic space. The company’s plan to roll out a rebate‑free pharmacy benefit model by 2027, with an expected 50% adoption of the new model by EverNorth and 80% adoption of the Cigna Healthcare guarantee plan, preserves margin integrity while opening a larger customer footprint. The firm’s disciplined pricing strategy, evidenced by the 88% medical loss ratio in the quarter, shows effective cost management even in a high‑cost environment, reinforcing confidence in its pricing power. The integration of AI‑driven digital tools—such as real‑time cost trackers and provider‑matching tools—offers scalable enhancements to member engagement, potentially translating into higher customer retention and premium growth. Strategic investments, notably the Shield Health Solutions acquisition, position the company to capture hospital and health‑system pharmacy opportunities, extending its specialty footprint into high‑volume clinical sites. The partnership ecosystem, including collaborations with Headspace for mental health, Progyny for fertility, and Caret for employer benefits, creates cross‑sell opportunities that could increase the share of wallet in existing accounts. Finally, the FTC settlement and the resulting 7 billion dollar out‑of‑pocket relief over ten years provide a tangible, long‑term cost‑reduction catalyst that can improve member satisfaction and drive plan renewals, creating a virtuous cycle of growth and profitability.
Cigna’s emphasis on customer‑centric innovation, such as the Clarity platform that offers a single digital front door for pharmacy, dental, and supplemental services, signals a shift toward integrated, value‑based care models that align with payer and provider incentives for improved outcomes. By leveraging data analytics to personalize care pathways and streamline authorization processes, the company reduces administrative burden, potentially lowering the medical loss ratio over time and improving its risk‑sharing profile. The firm’s commitment to expanding generics and biosimilars—highlighted by its zero out‑of‑pocket initiatives for Humira and Stellara—places it at the forefront of the upcoming 100 billion dollar specialty drug savings window, a sector projected to grow at double‑digit rates. The ability to capture market share in specialty pharmacy, a business that now accounts for roughly 35% of the company’s revenue, suggests a structural shift that could insulate the firm from the volatility seen in traditional insurance segments. The strategic focus on employer‑sponsored plans, particularly in the middle and select markets, aligns with a demographic that is less sensitive to macroeconomic swings and more oriented toward comprehensive benefits packages. Moreover, the company’s shift away from Medicare Advantage and the Obamacare business eliminates the regulatory headwinds and margin compression associated with those lines, freeing capital to invest in higher‑growth platforms. The firm’s capital allocation strategy—returning over 5 billion dollars to shareholders and maintaining a debt‑to‑capitalization ratio below 43%—provides a buffer for future acquisitions or investment in technology infrastructure that could accelerate the rollout of its new PBM model. Collectively, these initiatives represent catalysts that the market may have undervalued, positioning the company for sustainable long‑term earnings expansion.
The company’s forward guidance for 2026, projecting adjusted EPS of at least 30.25 and revenue of approximately 280 billion, remains in line with its multiyear growth trajectory, underscoring management’s confidence in execution. The forecasted medical cost ratio of 83.7% to 84.7% suggests a moderate increase, but the firm’s margin improvement plan and pricing actions in the stop‑loss and individual exchange businesses indicate that it is actively working to offset this trend. By projecting a first‑quarter medical loss ratio below 81%, the company signals a seasonality advantage that could provide a cushion against year‑over‑year cost pressure. The 2026 cash flow guidance of roughly 9 billion in operating cash, while lower than 2025, remains healthy relative to the capital deployment of 1.3 billion in cap‑ex and 1.6 billion in dividends, preserving upside potential for future growth. Importantly, the firm’s commitment to a 40% debt‑to‑capitalization target by 2028 reflects a disciplined approach to leverage that can support continued expansion of its pharmacy benefit services platform. The planned investment in the new rebate‑free model, projected to start generating earnings in the latter half of 2026, aligns with the company’s strategic focus on long‑term value creation. The company's robust share repurchase program, which reduced the share count and boosted earnings per share, will enhance shareholder value if the company continues to execute on its growth plan. Together, these financial drivers support a bullish thesis that the market may have underestimated the firm’s ability to sustain and grow earnings in a complex regulatory environment.
The company’s digital transformation, highlighted by AI‑powered tools and a seamless integration platform for member engagement, offers a clear path to differentiation in a highly competitive health‑services marketplace. By providing real‑time cost visibility and provider matching, the firm reduces uncertainty for members, thereby increasing plan loyalty and reducing churn. The integration of these tools across its three business platforms—specialty pharmacy, pharmacy benefit services, and employer health benefits—creates operational synergies that can lower per‑member acquisition costs. The expansion of the digital front door through the Clarity platform simplifies the customer experience, potentially driving higher utilization of its own services and improving data capture for future predictive analytics. The company's focus on mental health partnerships, such as its collaboration with Headspace, addresses a growing societal need while creating cross‑sell opportunities within its existing employer‑sponsored plans. These digital and partnership initiatives collectively enhance the company's competitive moat, allowing it to capture incremental revenue in a crowded market. The ability to scale these technologies across its vast member base further amplifies their impact on profitability, positioning the firm for continued upside.
The strategic shift toward a pharmacy benefit management model that eliminates rebates aligns the company with regulatory trends favoring transparency and cost containment, potentially positioning it as an industry leader in the evolving PBM landscape. The company’s proactive engagement with the FTC and the passage of federal PBM reform legislation demonstrate its ability to navigate regulatory uncertainty and shape policy outcomes. The new rebate‑free model promises a more predictable margin profile while reducing the risk associated with negotiated rebates, a vulnerability in the traditional PBM business. By shifting the revenue mix toward fee‑based earnings, the company mitigates the volatility that has historically plagued PBMs due to changes in manufacturer pricing or insurer negotiations. The model’s emphasis on patient‑centric cost savings could attract employers seeking to control pharmacy spend, driving further market penetration. The company’s ability to secure high‑profile clients, such as its guarantee plan adoption by major employers, signals market acceptance of this new model. This regulatory and market alignment positions the company to capture a larger share of the growing pharmacy benefit services segment, a trend that other PBMs may struggle to replicate due to legacy contracts and rebate structures. Consequently, the market may have undervalued the firm’s advantage in this structural shift, presenting a bullish opportunity.

Bear case

The new rebate‑free pharmacy benefit model, while positioned as a cost‑containing innovation, introduces significant transition risk that could erode margins in the short to medium term. The company acknowledges that investment spending for the new model will be back‑half weighted in 2026, implying a potential earnings dip before the model begins to generate benefits. Even though management claims the margin profile will remain unchanged, the elimination of rebates removes a key revenue stream that has historically buffered PBM earnings during periods of high drug prices. The adoption rate of the new model, projected at 50% for EverNorth by 2028 and 80% for Cigna Healthcare in 2027, is uncertain and may lag due to client inertia, contractual constraints, or competitive offerings from legacy PBMs. Delayed adoption could compress earnings, increase customer attrition, and erode the company’s competitive position against more established PBM partners who continue to leverage rebate structures. In addition, the firm’s cash flow guidance for 2026 indicates a 9 billion operating cash forecast, lower than 2025, partly due to the reduced contribution from PBS, suggesting liquidity pressure that could constrain future investment or share repurchase plans.
The company’s exit from Medicare Advantage and the shrinking of its Obamacare business remove a historically stable, high‑margin revenue source that could have provided a cushion during economic downturns. By concentrating more heavily on employer‑sponsored plans, Cigna exposes itself to market concentration risk, as a small number of large employers can exert pricing pressure or shift to alternative providers. The employer‑plan segment also tends to be more sensitive to macroeconomic conditions, with higher churn during recessions or when businesses face hiring freezes. The company’s projected flat membership growth of 18.1 million in 2026, coupled with a potential decline in individual exchange customers, signals limited upside and potential vulnerability to external pressures such as rising unemployment or tightening credit markets. The shift away from a diversified portfolio may leave the firm exposed to higher concentration risk and reduce its ability to offset losses in one segment with gains in another.
The medical loss ratio (MLR) for the quarter rose to 88%, higher than analyst expectations, reflecting rising medical costs and potential margin compression. The firm’s guidance for a medical cost ratio of 83.7% to 84.7% in 2026 acknowledges a continuing elevated cost environment, suggesting that pricing actions may not fully counterbalance cost growth. While the company claims a 81% MLR in the first quarter, seasonal factors may not fully offset the overall upward trend, and any unexpected spikes in medical costs—such as new high‑price specialty drugs or changes in utilization—could further erode profitability. The company’s heavy reliance on cost‑containment through generics and biosimilars may prove insufficient if the market shifts toward higher‑priced branded therapies or if manufacturers resist biosimilar adoption due to pricing or exclusivity battles. Thus, the firm faces significant risk from escalating medical costs that could squeeze its operating margins over time.
The reliance on digital and AI tools to reduce administrative burden, while promising, introduces integration complexity and data privacy concerns that could hamper adoption and operational efficiency. The company’s plans to deploy new technologies across its three platforms—specialty pharmacy, PBM, and employer health benefits—require robust IT infrastructure, data security protocols, and change management. Any failure in deployment, system downtime, or data breaches could result in customer dissatisfaction, regulatory fines, and reputational damage. Moreover, the effectiveness of these tools in reducing prior authorization volume, while claimed to be 15% in the past year, has not been independently verified, and further reductions may prove more challenging in practice. Thus, the company’s digital strategy carries execution risk that could undermine its projected cost savings and member engagement improvements.
The company’s capital allocation plan—returning over 5 billion dollars to shareholders—while attractive to investors, could limit the capital available for strategic acquisitions or technology investments needed to sustain long‑term growth. The planned 1.6 billion dollar dividend increase and ongoing share repurchases could dilute the company’s ability to invest in emerging opportunities, such as advanced analytics, telehealth, or new payer platforms. In an industry where innovation is rapid and competitors are continuously building new capabilities, limited capital for R&D and acquisitions may leave Cigna behind, reducing its competitive advantage and eroding market share. The company’s debt‑to‑capitalization ratio of 43% may appear healthy, but the 1.3 billion dollar cap‑ex outlay in 2026 could increase leverage and expose the firm to refinancing risk, especially if interest rates rise or credit markets tighten.

The new rebate‑free pharmacy benefit model, while positioned as a cost‑containing innovation, introduces significant transition risk that could erode margins in the short to medium term. The company acknowledges that investment spending for the new model will be back‑half weighted in 2026, implying a potential earnings dip before the model begins to generate benefits. Even though management claims the margin profile will remain unchanged, the elimination of rebates removes a key revenue stream that has historically buffered PBM earnings during periods of high drug prices. The adoption rate of the new model, projected at 50% for EverNorth by 2028 and 80% for Cigna Healthcare in 2027, is uncertain and may lag due to client inertia, contractual constraints, or competitive offerings from legacy PBMs. Delayed adoption could compress earnings, increase customer attrition, and erode the company’s competitive position against more established PBM partners who continue to leverage rebate structures. In addition, the firm’s cash flow guidance for 2026 indicates a 9 billion operating cash forecast, lower than 2025, partly due to the reduced contribution from PBS, suggesting liquidity pressure that could constrain future investment or share repurchase plans.
The company’s exit from Medicare Advantage and the shrinking of its Obamacare business remove a historically stable, high‑margin revenue source that could have provided a cushion during economic downturns. By concentrating more heavily on employer‑sponsored plans, Cigna exposes itself to market concentration risk, as a small number of large employers can exert pricing pressure or shift to alternative providers. The employer‑plan segment also tends to be more sensitive to macroeconomic conditions, with higher churn during recessions or when businesses face hiring freezes. The company’s projected flat membership growth of 18.1 million in 2026, coupled with a potential decline in individual exchange customers, signals limited upside and potential vulnerability to external pressures such as rising unemployment or tightening credit markets. The shift away from a diversified portfolio may leave the firm exposed to higher concentration risk and reduce its ability to offset losses in one segment with gains in another.
The medical loss ratio (MLR) for the quarter rose to 88%, higher than analyst expectations, reflecting rising medical costs and potential margin compression. The firm’s guidance for a medical cost ratio of 83.7% to 84.7% in 2026 acknowledges a continuing elevated cost environment, suggesting that pricing actions may not fully counterbalance cost growth. While the company claims a 81% MLR in the first quarter, seasonal factors may not fully offset the overall upward trend, and any unexpected spikes in medical costs—such as new high‑price specialty drugs or changes in utilization—could further erode profitability. The company’s heavy reliance on cost‑containment through generics and biosimilars may prove insufficient if the market shifts toward higher‑priced branded therapies or if manufacturers resist biosimilar adoption due to pricing or exclusivity battles. Thus, the firm faces significant risk from escalating medical costs that could squeeze its operating margins over time.
The reliance on digital and AI tools to reduce administrative burden, while promising, introduces integration complexity and data privacy concerns that could hamper adoption and operational efficiency. The company’s plans to deploy new technologies across its three platforms—specialty pharmacy, PBM, and employer health benefits—require robust IT infrastructure, data security protocols, and change management. Any failure in deployment, system downtime, or data breaches could result in customer dissatisfaction, regulatory fines, and reputational damage. Moreover, the effectiveness of these tools in reducing prior authorization volume, while claimed to be 15% in the past year, has not been independently verified, and further reductions may prove more challenging in practice. Thus, the company’s digital strategy carries execution risk that could undermine its projected cost savings and member engagement improvements.
The company’s capital allocation plan—returning over 5 billion dollars to shareholders—while attractive to investors, could limit the capital available for strategic acquisitions or technology investments needed to sustain long‑term growth. The planned 1.6 billion dollar dividend increase and ongoing share repurchases could dilute the company’s ability to invest in emerging opportunities, such as advanced analytics, telehealth, or new payer platforms. In an industry where innovation is rapid and competitors are continuously building new capabilities, limited capital for R&D and acquisitions may leave Cigna behind, reducing its competitive advantage and eroding market share. The company’s debt‑to‑capitalization ratio of 43% may appear healthy, but the 1.3 billion dollar cap‑ex outlay in 2026 could increase leverage and expose the firm to refinancing risk, especially if interest rates rise or credit markets tighten.

Depreciation And Amortization By Type Breakdown of Revenue (2025)

Product and Service Breakdown of Revenue (2025)

Peer comparison

Companies in the Healthcare Plans

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	CI	Cigna Group	-	-	-	31.46 Bn
2	MOH	Molina Healthcare, Inc.	-	-	-	3.77 Bn
3	ELV	Elevance Health, Inc.	-	-	-	30.95 Bn
4	PGNY	Progyny, Inc.	-	-	-	-
5	UNH	Unitedhealth Group Inc	-	-	-	78.39 Bn
6	HUM	Humana Inc	-	-	-	12.37 Bn
7	PFHO	Pacific Health Care Organization Inc	-	-	-	-
8	CNC	Centene Corp	-	-	-	17.40 Bn

Research Tools

Cigna Group (NYSE: CI)

About

Investment thesis

Bull case

Bear case

Depreciation And Amortization By Type Breakdown of Revenue (2025)

Product and Service Breakdown of Revenue (2025)

Peer comparison

Research Tools

Cigna Group (NYSE: CI)

About

Investment thesis

Bull case

Bear case

Depreciation And Amortization By Type Breakdown of Revenue (2025)

Product and Service Breakdown of Revenue (2025)

Peer comparison

Create an account

Sign In

Reset Password